Eli Lilly and Company $LLY Shares Sold by Denali Advisors LLC

Denali Advisors LLC lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 5.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,776 shares of the company’s stock after selling 740 shares during the quarter. Eli Lilly and Company makes up about 1.0% of Denali Advisors LLC’s holdings, making the stock its 13th biggest position. Denali Advisors LLC’s holdings in Eli Lilly and Company were worth $9,959,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Cookson Peirce & Co. Inc. raised its holdings in Eli Lilly and Company by 4.0% during the second quarter. Cookson Peirce & Co. Inc. now owns 14,833 shares of the company’s stock worth $11,563,000 after purchasing an additional 575 shares in the last quarter. Brookstone Capital Management grew its position in shares of Eli Lilly and Company by 15.1% during the second quarter. Brookstone Capital Management now owns 41,767 shares of the company’s stock worth $32,559,000 after acquiring an additional 5,471 shares during the last quarter. Phillips Financial Management LLC grew its position in shares of Eli Lilly and Company by 6.1% during the second quarter. Phillips Financial Management LLC now owns 1,301 shares of the company’s stock worth $1,015,000 after acquiring an additional 75 shares during the last quarter. Jacobsen Capital Management grew its position in shares of Eli Lilly and Company by 15.9% during the second quarter. Jacobsen Capital Management now owns 1,563 shares of the company’s stock worth $1,218,000 after acquiring an additional 214 shares during the last quarter. Finally, FNY Investment Advisers LLC grew its position in shares of Eli Lilly and Company by 441.9% during the second quarter. FNY Investment Advisers LLC now owns 1,138 shares of the company’s stock worth $887,000 after acquiring an additional 928 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insiders Place Their Bets

In other Eli Lilly and Company news, Director Gabrielle Sulzberger acquired 117 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the transaction, the director directly owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director J Erik Fyrwald acquired 1,565 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the transaction, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 4,514 shares of company stock worth $2,894,841. 0.14% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. DZ Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Guggenheim reiterated a “buy” rating and issued a $948.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, October 16th. BMO Capital Markets lifted their price objective on shares of Eli Lilly and Company from $840.00 to $930.00 and gave the company an “outperform” rating in a research report on Monday. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Finally, Leerink Partners reiterated a “market perform” rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $938.61.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $799.85 on Wednesday. The firm has a market capitalization of $757.03 billion, a P/E ratio of 52.28, a PEG ratio of 1.16 and a beta of 0.47. Eli Lilly and Company has a one year low of $623.78 and a one year high of $935.63. The company’s fifty day moving average is $759.77 and its two-hundred day moving average is $766.43. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business’s revenue was up 37.6% on a year-over-year basis. During the same period in the previous year, the firm earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.